Tuberculosis vaccine

Tuberculosis killed so predictably that the first useful vaccine against it had to be grown more like a lineage than manufactured like a pill. Calmette and Guerin did not discover a magic molecule that shut tuberculosis down. Starting in 1908, they took Mycobacterium bovis, the cattle relative of the human TB pathogen, and kept passing it through a bile-containing culture medium for years until it lost enough virulence to train the immune system without causing the full disease. That long discipline mattered. Tuberculosis was a chronic intracellular infection, not the sort of fast obvious enemy that yielded quickly to a single lab trick. The tuberculosis vaccine emerged when bacteriology, animal testing, and the live-vaccine logic established by the smallpox vaccine finally overlapped.

The process was slow by design. A review in FEMS Microbiology notes that Calmette and Guerin attenuated the organism over about 230 passages across 13 years before first using BCG in humans in 1921. The first documented human administration came on July 18, 1921, in France. That date matters because it marks the moment when one of medicine's deadliest killers finally met a preventive tool that could scale beyond sanatoria and hygiene campaigns. It was not a sterilizing shield. It was a reduction in the odds that infected infants would progress to the most catastrophic forms of disease.

Path-dependence shaped the vaccine from the beginning. Once Calmette and Guerin chose live attenuation rather than killed bacilli or a purified toxin approach, everything downstream followed from that choice: how the vaccine was cultured, how potency was judged, how it was stored, and who could safely receive it. The method also made the product unusually biological. BCG was not one frozen formula. It was a living strain being maintained in laboratories, shipped across borders, and grown again under slightly different conditions. That gave public health a workable vaccine, but it also created a second problem that only appeared after success.

Founder-effects explain that second problem. BCG spread globally as seed lots were shared with laboratories that then maintained their own daughter strains. PubMed reviews on BCG phylogeny describe how those strains drifted genetically over time, especially before lyophilized seed-lot controls were imposed. WHO later kept freeze-dried seed lots from 1956 onward specifically to prevent further deviation from the original vaccine. In other words, the vaccine behaved like a domesticated population. Early export decisions created lineages, and those lineages acquired their own laboratory histories. One invention became a family of related vaccines.

The vaccine's reputation nearly died in Germany before the strain itself did. In Lübeck in 1930, contaminated oral BCG doses given to 251 newborns caused a disaster in which 72 infants died of tuberculosis. Later investigations showed contamination with virulent tuberculosis bacilli in the local laboratory, not reversion of BCG itself. The distinction was scientifically decisive and politically fragile. One contamination event threatened to discredit a tool that had already been given safely to large numbers of infants elsewhere. The episode forced vaccine production standards, animal testing discipline, and custody controls to become part of the invention rather than mere packaging around it.

What BCG ultimately achieved was narrower than early hopes but larger than its critics admit. CDC and WHO both still emphasize the same bargain: the vaccine gives infants and young children meaningful protection against severe tuberculosis, especially meningitis and miliary disease, while protection against adult pulmonary tuberculosis is far more variable. That sounds like a limitation, and it is. But it also explains why BCG endured for a century while so many proposed replacements remained experimental. A partial vaccine against the deadliest childhood outcomes was still worth building national programs around.

Seen through the adjacent possible, the tuberculosis vaccine was an early twentieth-century compromise that kept compounding. The smallpox vaccine proved that live biological material could educate immunity. Pasteurian bacteriology made serial passage thinkable. Calmette and Guerin showed that attenuation could be engineered patiently enough to matter. Then public health systems, WHO seed-lot standards, and decades of neonatal vaccination turned that fragile laboratory lineage into the only licensed TB vaccine the world still has. BCG never solved tuberculosis in the broad adult-transmission sense. It solved a narrower and still vital problem: keeping childhood TB from becoming a routine death sentence.